This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings
by Zacks Equity Research
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
Integra (IART) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.
VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid
by Zacks Equity Research
The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.
Amedisys (AMED) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.
Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings
by Zacks Equity Research
Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.
Demand for Nutrition Line to Drive Abbott (ABT) Q1 Earnings
by Zacks Equity Research
Two additional regulatory approvals in Europe are expected to have widened Abbott's (ABT) global Panbio customer base through Q1, contributing to the top line.
Why Elanco Animal Health Incorporated (ELAN) Might be Well Poised for a Surge
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Elanco Animal Health Incorporated (ELAN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 33.33% and 8.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 350.00% and 5.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Elanco (ELAN) Ahead of Earnings?
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bayer Initiates a Phase III Study in Heart Failure Patients
by Zacks Equity Research
Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.
Bayer (BAYRY) Submits Applications for Heart Failure Drug
by Zacks Equity Research
Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.
Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of -45.83% and -9.94%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Elanco (ELAN) This Earnings Season?
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates for the first quarter of 2019.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2019.
New Strong Sell Stocks for February 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Elanco (ELAN) Surges: Stock Moves 5.3% Higher
by Zacks Equity Research
Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
New Strong Sell Stocks for January 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals
by Zacks Equity Research
Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.
Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
by Zacks Equity Research
Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.